最新ニュース Novo Nordisk (NYSE:NVO) 株価情報

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Equities

News

Markets

LCID

RIVN

TSLA

米国株は反発し、結果はまちまちにダウ平均は0.8％近く下落し、39,112.16ドルでした。一方、S&amp;P 500は0.4％以上上昇し、5,469.30ドルでレギュラーセッションを終えました。ナスダック指数はほぼ1.3％上昇し、17,717.65ドルで取引を終了しました。これらは、小売トレーダーや投資家の関心を集めたトップ銘柄です。

マイクロンが相場を牽引か　本日注目すべき株式

Health Care

Global

「ノーボ・ノルディスク (NYSE:NVO) は、同社の減量薬の需要増加に対応するため、米国での製造拠点の拡大に41億ドルを投資する予定だ。出来事：ノルウェーの製薬会社は、同社が発表したリリースの中で、北カロライナ州のローリー近くに新しい140万平方フィートの製造工場を建設する予定で、これにより同社製造拠点の規模が倍増するという。 この追加生産能力は、2027年から2029年の間に運用される予定だ。

ノーボ・ノルディスク　米製造拠点に41億円を投資

Novo Nordisk AS

Novo Resources Corp Warrants (27/08/2023)

Novo Integrated Sciences, Inc. - Common Stock

Novo Integrated Sciences Inc

Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable options, 15 are puts, totaling $739,514, and 5 are calls, amounting to $274,325.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $95.0 to $135.0 for Novo Nordisk over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's significant trades, within a strike price range of $95.0 to $135.0, over the past month.
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728066812_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.2</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$110.00</td>
<td>$151.2K</td>
<td>1.9K</td>
<td style="text-align: right;">559</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.45</td>
<td>$4.3</td>
<td>$4.31</td>
<td>$95.00</td>
<td>$86.1K</td>
<td>211</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.0</td>
<td>$5.85</td>
<td>$5.93</td>
<td>$120.00</td>
<td>$69.5K</td>
<td>902</td>
<td style="text-align: right;">153</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.35</td>
<td>$135.00</td>
<td>$65.2K</td>
<td>908</td>
<td style="text-align: right;">151</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.52</td>
<td>$2.49</td>
<td>$2.52</td>
<td>$115.00</td>
<td>$62.7K</td>
<td>3.5K</td>
<td style="text-align: right;">581</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 4,698,394, the NVO's price is down by -0.73%, now at $114.24. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 33 days.</li>
</ul>
<h3>Professional Analyst Ratings for Novo Nordisk</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $160.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Novo Nordisk's Options: A Look at What the Big Money is Thinking

Thursday, The FDA determined the shortage of Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
Tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022 due to increased demand.
The U.S. health regulator <a target="_blank" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize" rel="noreferrer noopener">reminded</a> compounders of the legal restrictions on making copies of FDA-approved drugs.
The FDA noted that Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide (Wegovy, Ozempic) is still in shortage.
Despite semaglutide being the active ingredient in Hims &amp; Hers Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) compounded GLP-1 product, a Truist analyst notes that the recent FDA commentary has reignited investor concerns about the long-term viability of compounded GLP-1 treatments once <a target="_blank" href="https://www.benzinga.com/news/24/10/41164688/hims-hers-health-stock-is-tumbling-thursday-heres-why" rel="noreferrer noopener">the supply shortage ends</a>.
Truist&#8217;s consumer survey reveals that approximately 10% of consumers currently use compounded GLP-1 medications, while 14% are on branded versions.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40944130/hims-hers-to-offer-access-to-compounded-diabetes-and-weight-loss-drugs-for-just-99month-to-certain-p" rel="noreferrer noopener">Hims &amp; Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel</a>.
Many people opting for compounded GLP-1s cite lower costs as the main reason, while others note that their primary care physicians are hesitant to prescribe the branded versions.
Hims &amp; Hers Health&#8217;s assertion that demand for its weight loss service could remain strong, even after supply shortages ease, as long as the company operates within compounding regulations and respects branded drug patents.
Based on third-quarter card data analysis, the analyst notes that Hims &amp; Hers Health&#8217;s Q3 2024 revenue is expected to exceed the company&#8217;s guidance range of $375 million to $380 million by approximately $5 million to $10 million.
The analyst also highlights that Hims &amp; Hers Health&#8217;s average transaction price was up 14% sequentially at $126.9 vs. ~$111 in the second quarter of 2024. Net orders for 3Q24 increased 3% sequentially from 2Q24.
Truist maintains a Hold rating for Hims &amp; Hers Health with a <a target="_blank" href="https://www.benzinga.com/quote/HIMS/analyst-ratings" rel="noreferrer noopener">price target of $23</a>.
Price Action: HIMS stock is up 0.18% at $17.16 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41189500/tesla-cio-quits-before-major-robotaxi-event-exec-departures-continue-in-2024" target="_blank" rel="noreferrer noopener">Tesla CIO Quits Before Major Robotaxi Event, Exec Departures Continue in 2024</a>.</li>
</ul>
Photo by Vidmir Rais via Pixabay

Analyst Color

Biotech

Price Target

Analyst Ratings

Trading Ideas

General

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages

NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes.
Tirzepatide, branded as Mounjaro and produced by Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), has shown remarkable results in clinical trials. It offers greater weight loss than existing therapies like Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Ozempic (semaglutide).
In the SURMOUNT-4 trial, patients lost an average of 20.9% of their body weight in 36 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41168351/popular-weight-loss-drugs-like-ozempic-show-gap-between-clinical-trial-promises-and-real-world-us" rel="noreferrer noopener">Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals</a>.
The plan, currently under consultation, <a target="_blank" href="https://www.nice.org.uk/news/articles/consultation-on-nhs-england-proposals-for-a-phased-launch-of-obesity-injection" rel="noreferrer noopener">aims</a> to test various medication delivery models before expanding its availability.
Under draft guidance from an independent committee at the National Institute for Health and Care Excellence (NICE), tirzepatide has been recommended for patients living with obesity, with a maximum list price of 122 pounds ($159.6) per month for the highest dose.
The phased launch will integrate tirzepatide into community-based services and digital health platforms to expand accessibility.
The rollout will target up to 240,000 people in the first three years and evaluate cost-effective delivery models, including virtual clinics.
Eligible patients will be categorized based on their BMI and related health conditions. Initially, those with a BMI above 40 and three or more weight-related conditions, such as hypertension and cardiovascular disease, will qualify.
Obesity is a significant challenge for the NHS, with annual treatment costs reaching 11.4 billion pounds ($14.91 billion).
According to the Health Survey for England 2022, about 64% of adults in the country are overweight or obese.
The consultation period for the rollout plan is currently open, with final guidance from NICE expected later this year.
Earlier this week, Eli Lilly announced a&nbsp;$4.5 billion&nbsp;investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing&nbsp;and drug development, as the company inches closer to becoming the first pharma company <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41141028/eli-lilly-invests-4-5b-in-new-medicine-foundry-for-advanced-drug-manufacturing-to-push-us-pharma-" rel="noreferrer noopener">in the $1 trillion club</a>.
Price Action: LLY stock is down 0.23% at $883.56 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41184148/novo-nordiskastrazenecas-manufacturing-partner-thermo-fisher-questioned-over-manufacturing-lapses" target="_blank" rel="noreferrer noopener">Novo Nordisk/AstraZeneca&#8217;s Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses</a>.</li>
</ul>
Photo via Company

Government

Large Cap

England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access

Thermo Fisher Scientific&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) one of the largest contract drug manufacturing sites in the U.S., has repeatedly been flagged for regulatory violations.
Thermo Fisher&#8217;s Greenville facility manufactures around 40 medicines, including Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) weight-loss <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35142181/weight-loss-drug-boom-has-another-ripple-effect-rapid-growth-expected-in-fill-finish-market" rel="noreferrer noopener">drug Wegovy (semaglutide)</a>.
Recently, Stephen&#8217;s analyst said that Thermo Fisher&#8217;s pharma services assets, especially its contract development and manufacturing organization (CDMO), are well positioned. The company is set to capitalize on growth opportunities in the injectables sector, driven by GLP-1 demand and biologics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127566/industry-leader-thermo-fishers-contract-services-positioned-for-growth-amid-popular" rel="noreferrer noopener">drug substance production</a>.
Over the past decade, the Greenville plant has been cited for issues related to contamination prevention, including two incidents earlier this year, Reuters noted, citing FDA documents.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39930516/thermo-fisher-q2-earnings-marginal-revenue-dip-completes-olink-acquisition-lifts-annual-profit-outl" rel="noreferrer noopener">Thermo Fisher Q2 Earnings: Marginal Revenue Dip, Completes Olink Acquisition, Lifts Annual Profit Outlook</a>.
Despite these concerns, the FDA did not take regulatory action, stating that the issues had been resolved to its satisfaction and that there was no evidence that patients had been harmed as a result.
During a recent inspection in May, the FDA identified manufacturing problems with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Beyfortus. The respiratory syncytial virus (RSV) preventive drug for infants and toddlers scored <a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33262341/astrazeneca-sanofis-respiratory-syncytial-virus-treatment-scores-fda-approval-to-prevent-infectio" rel="noreferrer noopener">FDA approval in 2023</a>.
The Reuters report highlighted that the FDA identified 17 deficiencies during the Beyfortus audit, including insufficient visual inspections for particulate matter in injectable drugs and issues with staff handling of sterile components.
The agency noted that Thermo Fisher&#8217;s equipment sterilization procedures were inadequate, and visual inspections for injectable drug contaminants failed.
Thermo Fisher has since addressed these issues, providing the FDA with the necessary data on drug safety, including control over bubble size in injectable medications. However, experts remain concerned about the plant&#8217;s approach to quality control.
In July, Merck &amp; Co Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Phase 2b/3 trial (MK-1654-004) of&nbsp;clesrovimab (MK-1654) to protect infants from respiratory syncytial virus (RSV) disease met its primary safety <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39916077/merck-competes-with-sanofiastrazeneca-as-its-rsv-treatment-drug-meets-primary-goal-in-late-stage-" rel="noreferrer noopener">and efficacy endpoints</a>.
Price Action: TMO stock is down 0.39% at $598.59 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41182921/rivians-production-forecast-hits-bump-supply-shortage-sends-shares-tumbling" target="_blank" rel="noreferrer noopener">Rivian&#8217;s Production Forecast Hits Bump, Supply Shortage Sends Shares Tumbling</a></li>
</ul>
Photo via Shutterstock

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses

The demand for GLP-1 agonists, including Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy (semaglutide), a class of drugs used to manage diabetes and obesity, continues to grow.
Though initially developed for type 2 diabetes, GLP-1s have gained attention for their effectiveness in weight management. The FDA approval expanded use for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37567088/novo-nordisks-game-changer-fda-approves-weight-loss-sensation-wegovy-for-heart-health-potential-i" rel="noreferrer noopener">cardiovascular indication for Wegovy</a> and potential future applications for chronic kidney disease and non-alcoholic steatohepatitis (NASH) further underscores the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic" rel="noreferrer noopener">promise of these treatments</a>.
The Forbes report <a target="_blank" href="https://www.forbes.com/sites/joshuacohen/2024/10/02/weight-loss-from-glp-1-drugs-not-as-robust-in-real-world-settings/" rel="noreferrer noopener">adds</a> that real-world evidence shows that weight loss from GLP-1 usage may not align with the outcomes seen in clinical trials.
A study published in the Journal of the American Medical Association (JAMA) revealed that patients, on average, achieved only a 3.7% weight reduction after one year on the drugs—lower than the results reported in controlled trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on" rel="noreferrer noopener">Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>.
While patients have high expectations for substantial weight loss, the findings suggest that most individuals did not experience the same degree of benefit as seen in clinical settings.
However, those who persisted with GLP-1 therapy saw results comparable to those in clinical trials.
In another study published in 2023, researchers observed a modest average weight loss of 2.2% over 72 weeks among type 2 diabetes patients on GLP-1s.
Additionally, a pre-print analysis this year found that the real-world effectiveness of GLP-1s was less pronounced than in randomized controlled trials.
This difference underscores the challenge of replicating clinical trial success in everyday medical settings, where factors like medication adherence and real-life conditions are involved.
Persistence with GLP-1 medications is a significant issue. Forbes reported that only 15% of patients who started GLP-1 drugs for weight loss remained on them after two years, citing Prime Therapeutics, a pharmacy benefit manager.
Discontinuation rates were high, with just 29% continuing treatment after one year and a mere 15% after two years.
Other studies, including findings from Blue Cross Blue Shield, show that many patients stop GLP-1 therapy early, often within the first month, before achieving meaningful weight loss.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" target="_blank" rel="noreferrer noopener">Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected</a>.</li>
</ul>
Photo via Shutterstock

Media

Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals

On Wednesday, the U.S. Department of Health and Human Services (HHS), working via the Centers for Medicare &amp; Medicaid Services (CMS), released final guidance for the second cycle of the <a href="https://www.benzinga.com/general/health-care">Medicare Drug Price Negotiation Program</a>.
This initiative <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
It also ensures that people with Medicare can access these negotiated prices, expanding on the groundwork laid in the first cycle of negotiations.
The first round of negotiations focused on 10 specific drugs. Medicare recipients should save approximately $1.5 billion in out-of-pocket costs when the new prices take effect in 2026.
By February 2025, CMS will select up to 15 additional drugs for the second round of negotiations. The selected drugs will undergo negotiations in 2025, with new prices becoming effective in 2027.
They include: 
<ul>
<li>Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes drug, <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">Ozempic,</a></li>
<li>Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) cancer drugs Ibrance and Xtandi</li>
<li>GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) asthma treatment Trelegy Ellipta</li>
<li>Teva Pharmaceutical Industries Ltd.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington&#8217;s disease drug Austedo, and</li>
<li>Abbvie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess.</li>
</ul>
CMS plans to improve patient-focused engagement during the second cycle of negotiations. It will also organize roundtable events and town hall meetings in 2025.
As Medicare Open Enrollment approaches on Oct. 15, beneficiaries can expect more cost-saving measures in the coming years. That includes a $2,000 annual cap on out-of-pocket drug costs starting in January 2025.
These changes build on other provisions of the Inflation Reduction Act, which was signed by President Joe Biden on Aug. 16, 2022. The legislation included a $35 monthly cap on insulin and free recommended vaccines for adults covered under Medicare Part D.
Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective from Oct. 1, 2024, to Dec. 31, 2024. Some Medicare beneficiaries could see daily savings ranging from $1 to as much as $3,854 on drugs included <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could" target="_blank" rel="noreferrer noopener">in the rebate program</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41162084/amazon-prime-video-ramps-up-ads-taking-on-netflix-and-disney-in-streaming-battle" target="_blank" rel="noreferrer noopener">Amazon Prime Video Ramps Up Ads, Taking on Netflix and Disney+ in Streaming Battle</a>.</li>
</ul>
Image: Shutterstock

ABBV

TEVA

Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are trading lower Thursday in possible sympathy with Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), after the U.S. Food and Drug Administration removed it from the weight-loss and diabetes drugs <a href="https://www.benzinga.com/markets/equities/24/09/40672154/eli-lilly-launches-discounted-mounjaro-and-zepbound-as-fight-against-compounded-imitations-escal">shortage list</a>.
What Happened: The FDA said in a <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize">statement</a> late Wednesday that Eli Lilly's supply of Mounjaro, which is used to treat diabetes, and weight-loss drug Zepbound can now keep up with current demand. 
Mounjaro had been on the regulator&#8217;s shortage list since late 2022, and Zepbound had been on the list since April.
&#8220;FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies,&#8221; the FDA said.
Hims &amp; Hers Health shares are under pressure on Thursday as the firm sells cheaper versions of the aforementioned drugs, known as compounded drugs. Hims &amp; Hers said in May that it would&nbsp;begin selling compounded versions&nbsp;of GLP-1 injections. Shares surged on the news and have more than doubled since the start of the year.
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/biotech/24/07/39656549/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo">EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO</a>
The limited supply for weight-loss and diabetes drugs from Lilly and rival Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) sparked a demand boom for compounded drugs, which are made by combining, mixing, or altering drug ingredients, per Reuters.
The report also indicates that regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage. When there is no shortage, compounded drug makers are reportedly unable to make &#8220;regular or inordinate amounts&#8221; of the drugs.
Lilly reportedly began selling vials of its lowest dose of Zepbound in the U.S. directly to consumers via its website to help push back against the rise of compounded versions of the drug. Novo Nordisk&#8217;s drugs were still listed on the FDA&#8217;s shortage list as of Thursday. 
HIMS Price Action: <a href="http://benzinga.com/quote/hims">Hims &amp; Hers Health shares</a> were down 8.92% at $17.26 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Natalia Varlei from Shutterstock.

Movers

Hims & Hers Health Stock Is Tumbling Thursday: Here's Why

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 64% leaning bullish and 35% bearish. Among these notable options, 8 are puts, totaling $451,772, and 9 are calls, amounting to $508,244.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $135.0 for Novo Nordisk during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 703.94 with a total volume of 3,639.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Novo Nordisk's big money trades within a strike price range of $70.0 to $135.0 over the last 30 days.
<h3>Novo Nordisk 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727895790_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.15</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$125.00</td>
<td>$127.5K</td>
<td>3.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$18.6</td>
<td>$17.6</td>
<td>$18.0</td>
<td>$115.00</td>
<td>$90.0K</td>
<td>114</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.95</td>
<td>$6.9</td>
<td>$6.95</td>
<td>$120.00</td>
<td>$86.8K</td>
<td>250</td>
<td>201</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.05</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$125.00</td>
<td>$86.1K</td>
<td>1.3K</td>
<td>120</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.0</td>
<td>$20.85</td>
<td>$20.85</td>
<td>$100.00</td>
<td>$83.3K</td>
<td>1.2K</td>
<td>40</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Following our analysis of the options activities associated with Novo Nordisk, we pivot to a closer look at the company's own performance.
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>With a volume of 4,460,331, the price of NVO is down -1.46% at $116.29. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>Professional Analyst Ratings for Novo Nordisk</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $160.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Novo Nordisk

RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.
The analyst highlights several key growth drivers for Tandem, positioning it for sustained growth over the coming years driven by expansion into the U.S. Type 1 market with a 40% pump penetration (Tandem has a one-third share), which is expected to rise to the mid-60s and Type 2 market with 6% penetration.
The company is also seeking deeper penetration within existing accounts through product innovations.
The analyst also added that the rise of GLP-1s class drugs is not a major threat to insulin pump adoption.
GLP-1 drugs such as Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide as Wegovy and Ozempic and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide as Zepbound and Mounjaro, have recently made waves.
RBC analyst highlights that insulin is essential for insulin-dependent patients, as GLP-1 medications cannot regenerate beta cells or halt their deterioration. As a result, the need for insulin remains.
The Type 2 diabetes population, which suffers from irreversible beta cell loss, is underserved.
The growing popularity of GLP-1 drugs may lead to earlier diagnoses of Type 2 diabetes and prompt insulin use, potentially expanding the market.
RBC initiated Tandem with an Outperform, with a price target of $65, citing a significant upside potential driven by earning revisions and multiple expansions.
RBC sees an opportunity for Tandem to achieve profitability over time and projects gross margins of 51% in 2024 or flat y/y to reflect the Mobi launch and investments in several ongoing R&amp;D initiatives.
The analyst sees a clear path for the company to reach its goal of approximately 65% margins, with Mobi accounting for about half of that progress. Further gains are anticipated from planned initiatives.
RBC projects breakeven for 2024, with positive adjusted EBITDA margins expected in the second half of the year.
Price Action: TNDM stock is down 0.37% at $40.92&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41146425/toyota-doubles-down-on-joby-aviation-500m-investment-powers-us-electric-air-taxi-certification-p" target="_blank" rel="noreferrer noopener">Toyota Doubles Down On Joby Aviation: $500M Investment Powers US Electric Air Taxi Certification, Production</a>.</li>
</ul>

Initiation

TNDM

Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says

Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is making a major move with a $4.5 billion investment to create the Lilly Medicine Foundry, a new research <a href="https://www.benzinga.com/quote/LLY/news">and manufacturing facility</a>.
The goal? To bolster its drug pipeline and develop faster, more efficient ways to bring treatments to market. This move builds on the massive success of its GLP-1 drugs, Mounjaro and Zepbound, which are revolutionizing the obesity treatment landscape and are projected to bring in nearly $19 billion in 2024.
<h2 class="wp-block-heading">From Molecules To Medicines, Says CEO Ricks</h2>
These drugs have quickly become some of the most talked-about products in the weight-loss market, alongside competitors like Novo Nordisk AS's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy.
Beyond obesity drugs, Eli Lilly's pipeline includes 11 obesity-related treatments and ambitious plans to develop therapies for Alzheimer's, ALS, and other neurological conditions. CEO David Ricks emphasized the facility's role in scaling innovative molecules into life-saving medicines: "The idea is to take molecules from a bench in a lab to scaled for medicines in a pharmacy, and this research and development site will do that work."
Read Also: <a href="https://www.benzinga.com/general/biotech/24/10/41141028/eli-lilly-invests-4-5b-in-new-medicine-foundry-for-advanced-drug-manufacturing-to-push-us-pharma-">Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries</a>
<h2 class="wp-block-heading">Eli Lilly Stock Chart Suggests Near-Term Headwinds</h2>
From a stock perspective, Eli Lilly has had a fantastic year, posting gains of 49% year-to-date and over 64% in the last 12 months. 
However, the technical signals suggest some headwinds in the near term.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="459" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091753/Screenshot-2024-10-02-at-6.45.52-PM.png" alt="" class="wp-image-576525" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091753/Screenshot-2024-10-02-at-6.45.52-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091753/Screenshot-2024-10-02-at-6.45.52-PM-300x219.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Eli Lilly stock is trading below key short-term moving averages, including the eight-, 20-, and 50-day simple moving averages (SMA), which traditionally signal a short-to-medium-term bearish outlook. However, the stock trades well above the 200-day SMA, suggesting the long-term remains bullish.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="459" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091802/Screenshot-2024-10-02-at-6.47.13-PM.png" alt="" class="wp-image-576526" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091802/Screenshot-2024-10-02-at-6.47.13-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091802/Screenshot-2024-10-02-at-6.47.13-PM-300x219.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The MACD (Moving Average Convergence/Divergence) indicator is negative at 6.28, reinforcing short-term selling pressure. The RSI (Relative Strength Index) lies in neutral territory at 40.89.
Yet, long-term investors might still see potential in the stock. With a 200-day moving average of $794.34, Eli Lilly could remain a solid investment for the future, particularly as its obesity drugs gain further market share.
While some volatility may persist in the short term, the long-term potential remains strong as Lilly continues to invest in its drug development pipeline.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation">Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation</a></li>
</ul>
Photo: Shutterstock

Technicals

Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges

On Wednesday, Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced a&nbsp;$4.5 billion&nbsp;investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41138388/lilly-announces-new-4-5-billion-site-the-lilly-medicine-foundry-to-drive-innovation-in-drug-produc" rel="noreferrer noopener">and drug development</a>.
As the company inches closer to becoming the first pharma company in the $1 trillion club, it aims to strengthen its standing as one of the top 10 most valuable firms in the U.S. by <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" rel="noreferrer noopener">outpacing its competitors</a>.
In a report, Eli Lilly said it plans to reinvest its revenues into R&amp;D, aiming to escape the pharmaceutical industry&#8217;s traditional boom-and-bust cycle.
The company says the new facility will allow Lilly to research new ways of producing medicines while scaling up the manufacturing of medicines for clinical trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke" rel="noreferrer noopener">Eli Lilly&#8217;s Early Alzheimer&#8217;s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market</a>.
The Medicine Foundry will be the first-ever facility of its kind to combine research and manufacturing in a single location. It will be located in&nbsp;Indiana&#8217;s&nbsp;LEAP Research and Innovation District in&nbsp;Lebanon, Indiana, and will expand the company&#8217;s investment there to more than&nbsp;$13 billion.&nbsp;
This new facility will add to Lilly&#8217;s previous manufacturing commitments in&nbsp;Lebanon, which include a $2.1 billion investment announced in May 2022 to expand its network for active ingredients and new modalities, such as genetic medicines.
In&nbsp;April 2023, the company announced an&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268657-1&amp;h=1606463900&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2023-04-17-Lilly-to-Make-Record-Breaking-Investment-in-Indiana-Manufacturing-Facilities&amp;a=additional+%241.6+billion" rel="noreferrer noopener">additional&nbsp;$1.6 billion</a> investment.
In&nbsp;May 2024, Lilly announced an&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268657-1&amp;h=647148840&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2024-05-24-Lilly-Increases-Manufacturing-Investment-to-9-Billion-at-Newest-Indiana-Site-to-Boost-API-Production-for-Tirzepatide-and-Pipeline-Medicines&amp;a=additional+%245.3+billion" rel="noreferrer noopener">additional&nbsp;$5.3 billion</a> commitment to enhance its capacity to manufacture active pharmaceutical ingredients for its latest diabetes and obesity medicines, marking the largest single investment in active pharmaceutical ingredients production in U.S. history.
Opening in late 2027, the facility will increase Lilly&#8217;s total capital commitment in&nbsp;the United States&nbsp;to more than&nbsp;$23 billion&nbsp;since 2020. It is trying to stay ahead of its close competitor, Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Once fully operational, the Medicine Foundry is expected to add 400 full-time jobs.
Price Action: At last check on Wednesday, LLY stock was down 0.39% at $881.00 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" target="_blank" rel="noreferrer noopener">Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation</a></li>
</ul>
Photo via Shutterstock

Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries

U.S. Pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is riding high on the popularity of weight loss drugs and is on the brink of becoming the world's first trillion-dollar pharmaceutical company.
According to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>, the company's market cap stood at $796.4 billion, and its enterprise value at $821.9 billion.
The stock had almost doubled since May 2022 and outpaced S&amp;P500 and NASDAQ when the company received FDA approval for Mounjaro (tirzepatide) as an adjunct to diet and exercise <a target="_blank" href="https://www.benzinga.com/general/biotech/22/05/27213975/fda-approves-eli-lillys-new-type-2-diabetes-treatment-tirzepatide" rel="noreferrer noopener">for type 2 diabetes</a>.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064204/newplot-1-1.png" alt="" class="wp-image-576166" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064204/newplot-1-1.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064204/newplot-1-1-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
In November, the FDA approved tirzepatide, dubbed Zepbound, <a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35680340/weight-loss-drug-competition-fda-approves-expanded-use-of-eli-lillys-blockbuster-tirzepatide-for-" rel="noreferrer noopener">for weight loss</a>.
In a Financial Times <a target="_blank" href="https://www.ft.com/content/ed81ca79-1fd6-48ea-8e50-246d0849c3f5" rel="noreferrer noopener">report</a>, CEO Dave Ricks recalls a time when Eli Lilly was struggling. In the late 2000s, the loss of patents on its psychiatric drugs, including Prozac and Cymbalta, pushed the company near all-time lows.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41118751/eli-lilly-eyes-new-trials-for-weight-loss-drugs-in-non-obese-patients" rel="noreferrer noopener">Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients</a>.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064215/newplot-2.png" alt="" class="wp-image-576167" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064215/newplot-2.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064215/newplot-2-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
However, the company's fortunes have since reversed, with Eli Lilly now investing $20 billion in production facilities to meet the growing demand for its blockbuster drugs, and it is trying to stay ahead of its close competitor Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
The company is also developing orforglipron, which could be the first small-molecule weight-loss pill when it launches in 2026, giving Eli Lilly a two-year lead before rivals catch up.
However, investors are cautious, noting that Eli Lilly's valuation is lofty, currently at $842 billion, 54x projected earnings over the next 12 months.
A top-10 shareholder of Eli Lilly told the Financial Times that investors are rushing into Eli Lilly, pushing it higher, but it's already priced for perfection. The shareholder warned that investors could face significant risks if concerns arise about competition from the ten other companies with weight-loss drugs or potential pricing pressures.
The company aims to strengthen its standing as one of the top 10 most valuable firms in the U.S. by outpacing its competitors.
Eli Lilly plans to reinvest its revenues into R&amp;D, aiming to escape the pharmaceutical industry's traditional boom-and-bust cycle.
CEO Ricks says the company is preparing for the future, particularly as it nears a "patent cliff" for its weight-loss drugs in the mid-2030s. By then, competition and pricing pressure could significantly affect profits.
The company is working on new treatments for obesity-related conditions, such as sleep apnea and cardiovascular disease, which could secure broader insurance coverage for its drugs.
Price Action: LLY stock closed at $884.55&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41127863/despite-nvidia-selloff-bidens-law-and-taiwan-semis-advantage-offer-growth-potential" target="_blank" rel="noreferrer noopener">Despite Nvidia Selloff, Biden's Law and Taiwan Semi's Advantage Offer Growth Potential</a>.</li>
</ul>
Photo via Eli Lilly and Company

Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation

Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective from October 1, 2024, to December 31, 2024.
The <a target="_blank" href="https://www.hhs.gov/about/news/2024/09/30/hhs-announces-cost-savings-for-prescription-drugs-thanks-to-medicare-inflation-rebate-program.html" rel="noreferrer noopener">program</a> aims to counter drug price hikes that exceed inflation, providing financial relief for over 822,000 Medicare beneficiaries who rely on these medications to treat conditions like cancer, osteoporosis, and pneumonia.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422798/doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy" rel="noreferrer noopener">Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk&#8217;s Wegovy</a>
HHS Secretary Xavier Becerra emphasized that the Biden administration&#8217;s prescription drug policies are making a tangible impact on seniors and people with disabilities by reducing out-of-pocket costs.
According to Chiquita Brooks-LaSure, CMS Administrator, some Medicare beneficiaries could see daily savings ranging from $1 to as much as $3,854 on drugs included in the rebate program.
For example, a cancer patient using Novartis&#8217; AGs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Kymriah could save up to $3,000.
Brooks-LaSure also noted that the law disincentivizes drug companies from raising prices faster than inflation, which helps protect Medicare beneficiaries from sharp price increases.
The Inflation Reduction Act&#8217;s initiatives extend beyond 2024. In August, the administration reached new agreements to reduce prices for ten additional high-cost drugs.
Once these prices take effect in 2026, Medicare is projected to save an estimated $6 billion, while beneficiaries could see a reduction of $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40397706/biden-administration-targets-6b-savings-through-medicare-drug-price-negotiations" rel="noreferrer noopener">out-of-pocket expenses</a>.
Starting in 2025, Medicare Part D enrollees will further benefit from a $2,000 annual cap on prescription drug costs, down from the current cap of $3,500 for those with high expenses.
According to some analysts,&nbsp;Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)&nbsp;blockbuster diabetes drug&nbsp;Ozempic might be included, along with several other well-known medications, in the next round of negotiations, which <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">is set for 2027</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41124151/tpg-gic-agree-to-buy-techem-for-7-5b-look-to-expand-across-europe-and-beyond" target="_blank" rel="noreferrer noopener">TPG, GIC Agree To Buy Techem For $7.5B: Look To Expand &#8216;Across Europe And Beyond&#8217;</a></li>
</ul>
Photo via Shutterstock

Regulations

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next

Novo Nordisk Says Co Has Mitigation Plans In Place To Minimize Or Prevent Any Production Disruption Due To The Potential Seaport Strikes

At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, renal, and metabolism diseases.
The company shared an &#8216;initial set of assets designated for acceleration based on exceptional potential.&#8217;
To maximize potential, the company plans to expedite enrollment with additional clinical trial sites, reallocate resources, and expand into additional indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market</a>.
The <a target="_blank" href="https://assets.roche.com/f/176343/x/f513f69de2/pharma_day_20240930_final_online_v02.pdf" rel="noreferrer noopener">selected</a> fast-tracked programs include:
<ul>
<li>CT-388 (RG6640) for obesity entered the Phase 2 stage of development in patients with or without type 2 diabetes and comorbidities.</li>
<li>Roche expects a commercial launch for CT-388 beyond 2028.</li>
<li>Trontinemab is currently in Phase 2 for Alzheimer&#8217;s. Potential launch in 2025-2028.</li>
<li>Anti-TL1A Inflammatory Bowel Disease candidate in Phase 3 stage of development.</li>
</ul>
Roche&#8217;s push into the obesity space follows the success of competitors like Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), which have seen significant demand for weight-loss drugs like Wegovy and Zepbound.
Additionally, Roche highlighted the financial potential of its obesity drug candidates, projecting that <a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36064233/roche-joins-bandwagon-to-challenge-novo-nordisk-eli-lilly-for-weight-loss-drugs" rel="noreferrer noopener">early-stage assets acquired</a> from Carmot Therapeutics (CT-388/CT-996/CT-868) could generate over 3 billion Swiss francs ($3.55 billion) in annual sales.
In July, Roche&nbsp;announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">type 2 diabetes and obesity</a>.
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
In line with its broader strategy, Roche plans to cut drug development costs by 20% and reduce the time it takes for drugs to move from discovery to the end of Phase 3 trials by 40%, aiming to launch 20 transformative medicines by 2030.
The company is targeting three times as many patients during the 2020-2029 period.
Monday, Roche <a target="_blank" href="https://www.prnewswire.com/news-releases/regor-enters-into-a-definitive-purchase-agreement-for-genentech-to-acquire-regors-portfolio-of-next-generation-cdk-inhibitors-for-the-treatment-of-breast-cancer-302262174.html" rel="noreferrer noopener">agreed</a> to acquire a portfolio of next-generation CDK inhibitors for breast cancer from Regor Pharmaceuticals.
Regor will receive an upfront cash payment of&nbsp;$850 million&nbsp;and is eligible for additional milestone cash payments.
Roche&#8217;s Genentech will be responsible for clinical development, manufacturing, and commercialization worldwide.
Regor will continue to manage the two ongoing Phase 1 trials to their completion.
The deal is expected to close in the fourth quarter of 2024.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41095043/spotify-recovers-after-3-hour-outage-impacting-thousands-of-users" target="_blank" rel="noreferrer noopener">Spotify Recovers After 3-Hour Outage Impacting Thousands of Users</a>.</li>
</ul>
Photo via Shutterstock

Eurozone

RHHBY

Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential

In a surprising twist, two of the most unlikely allies – billionaire Elon Musk and Sen. Bernie Sanders – are standing together on one issue: the high cost of health care in America. Both agree that Americans are being charged way too much for <a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear">essential medications like Ozempic</a> and Wegovy, which treat diabetes and obesity.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Bernie Sanders, a longtime advocate for affordable health care, has been vocal about Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the Danish company behind these drugs, charging American patients almost 10 times more than they charge in other countries like Germany.
<a href="https://www.benzinga.com/general/biotech/24/09/41010577/novo-nordisk-to-consider-ways-for-patients-to-affordably-access-weight-loss-drugs-ozempic-wegovy-">A month's prescription for Wegovy</a> costs $1,349 in the U.S., compared to $186 in Denmark, $140 in Germany, and $92 in the U.K.
Trending: Teens may never need wisdom teeth removed thanks to this MedTech Company –<a href="https://www.benzinga.com/money/triagenics"> Be an early investor for just $300 for 100 shares!</a>
During a recent subcommittee hearing, Sanders called out Novo Nordisk&#8217;s CEO and demanded that Americans be treated fairly. "All we are saying, Mr. Jørgensen, is treat the American people the same way that you treat people all over the world – stop ripping us off."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f6a8;&#x1f1fa;&#x1f1f8;SEN. BERNIE SANDERS: ELON IS RIGHT ABOUT SOLVING OBESITY &quot;Elon Musk, not one of my usual allies, recently tweeted that solving obesity reduces the risk of diseases like diabetes and improves quality of life. He's right—we need to make appetite inhibitors available to… <a href="https://t.co/vmPzNNc15B">pic.twitter.com/vmPzNNc15B</a>
&mdash; Mario Nawfal (@MarioNawfal) <a href="https://twitter.com/MarioNawfal/status/1838737435653460028?ref_src=twsrc%5Etfw">September 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Elon Musk, known for his clashes with Sanders over income inequality, surprised many by siding with the senator. He shared his struggles with weight and revealed he had used Wegovy to help him slim down.&nbsp;
Trending: Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500.</a>
"Solving obesity greatly reduces the risk of other diseases, especially diabetes, and improves quality of life," Sanders quoted Musk as saying. And Musk followed up with, "I really am with Bernie on this one."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I really am with Bernie on this one
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1838758206585094625?ref_src=twsrc%5Etfw">September 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Novo Nordisk's CEO, Lars Fruergaard Jørgensen, admitted that a huge chunk of the company's revenue from these drugs comes from the U.S., but he tried to shift the blame to PBMs, who he says pocket 74 cents of every dollar made. This system, he argued, keeps prices high because PBMs get paid more when the list price is higher.
Trending: General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"> investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50/share with a $1,000 minimum.</a>
Sanders wasn't buying it. He revealed that he had gotten a written promise from three major PBMs that they wouldn't drop coverage for Novo Nordisk's drugs if the company lowered its prices. But Jørgensen acted surprised and claimed he hadn't heard of any such deal.
The Federal Trade Commission (FTC) also released a <a href="https://www.ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdf">report</a> highlighting how pharmacy benefit managers (PBMs) are profiting at the expense of patients. These middlemen, who manage prescription drug benefits for insurers and employers, have been inflating drug prices and squeezing independent pharmacies.&nbsp;
According to a report, six major corporations manage about 90% of all prescriptions in the United States. This gives them the authority to set exorbitant medicine costs. Because of the high expense of prescription drugs, almost 30% of Americans have reported skipping dosages or limiting them.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
FTC Chair Lina M. Khan stated that the report &#8220;Details how PBMs can squeeze independent pharmacies that many Americans – especially those in rural communities – depend on for essential care. The FTC will continue using all our tools and authorities to scrutinize dominant players across health care markets and ensure Americans can access affordable health care.&#8221;
See Also: Are you richer than most people you know?<a href="https://www.benzinga.com/money/are-you-richer-than-most-people"> Here&#8217;s the net worth you need at every age to be above average.</a>
Mark Cuban, another billionaire entrepreneur and owner of Cost Plus Drugs, quickly responded to the FTC's findings. In a tweet, <a href="https://www.benzinga.com/personal-finance/24/07/39799717/patients-pay-the-price-as-drug-middlemen-profit-says-ftc-report-mark-cubans-take-anyone-surprise">he pointed out the obvious</a>: "Anyone surprised by this? Please share with every CEO, CFO, and HR person you know. If you are a shareholder or Wall Street analyst, ask your portfolio companies who their PBM is, not if they are being ripped off, but how badly."
In a country where health care costs are sky-high and outcomes lag behind many other developed nations, it's rare to see such agreement across the political spectrum. But when both a billionaire tech mogul and a democratic socialist senator are on the same side, it might be time to take notice.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
</ul>

Personal Finance

'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas">many investors&#8217; favorite stocks</a> over the last week — here&#8217;s a look at some of our top stories.
The Dow Jones Industrial Average hit a record high Friday as investors analyzed data showing continued progress in lowering inflation. Wall Street posted its third straight week of gains.
The S&amp;P 500 and Dow both rose about 0.6% for the week, while the Nasdaq climbed nearly 1%. The personal consumption expenditures index, the Federal Reserve&#8217;s preferred inflation measure, increased 2.2% in August compared to the previous year, coming in below economists&#8217; expectations. 
This followed the Federal Reserve&#8217;s 0.5% interest rate cut on Sept. 18, the first in <a href="https://www.benzinga.com/markets/equities/24/09/41074448/latest-inflation-data-cements-feds-interest-rate-call-s-p-500-hits-all-time-high-biden-adviser-b">more than four years</a>.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week&#8217;s most bullish and bearish posts that are worth another look.
<h3 class="wp-block-heading">The Bulls</h3>
&#8220;<a href="https://www.benzinga.com/news/24/09/41005053/apple-iphone-to-fuel-96-of-2025-revenue-analyst-says-a-safer-bet-than-ai-heavy-amazon-alphabet-micro">Apple iPhone To Fuel 96% Of 2025 Revenue, Analyst Predicts: A Safer Bet Than AI-Heavy Amazon, Alphabet, Microsoft, Meta?</a>&#8221; by <a href="https://www.benzinga.com/author/anusuya-lahiri-0">Anusuya Lahiri</a>, highlights an analyst&#8217;s projection that Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) will derive 96% of its 2025 revenue from iPhone sales, positioning it as a safer investment than AI-focused giants like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
&#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41059326/shiba-inu-soars-29-on-shi-stablecoin-update-lead-developer-shytoshi-kusama-teases-breakout">Shiba Inu Soars 29% On SHI Stablecoin Update: Lead Developer Shytoshi Kusama Teases Breakout</a>,&#8221; by <a href="https://www.benzinga.com/author/aniket-verma">Aniket Verma</a>, reports that Shytoshi Kusama teased the impending launch of the SHI stablecoin, which is seen as a crucial development for Shibarium, sparking excitement across the Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) ecosystem.
&#8220;<a href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic">Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users</a>,&#8221; by <a href="https://www.benzinga.com/author/vandana-singh">Vandana Singh</a>, reports that a new study found Novo Nordisk A/S&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide, sold as Ozempic and Wegovy, may lower the risk of opioid overdose in patients with both type 2 diabetes and opioid use disorder.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/general/education/24/09/41031059/after-fed-rate-cuts-is-tesla-nvidia-apple-or-amazon-the-best-investment-poll-reveals-top-magnif">After Fed Rate Cuts, Is Tesla, Nvidia, Apple, Or Amazon The Best Investment? Poll Reveals Top Magnificent 7 Stock</a>
<a href="https://www.benzinga.com/news/24/09/41034882/billionaire-tech-ceo-makes-cameo-in-zuckerbergs-meta-connect-show">Billionaire Tech CEO Makes Cameo In Zuckerberg&#8217;s Meta Connect Show</a>
<a href="https://www.benzinga.com/markets/equities/24/09/41023892/palantir-and-apa-amp-up-ai-alliance-multi-million-dollar-deal-to-transform-oil-gas-operations">Palantir And APA Amp Up AI Alliance: Multi-Million Dollar Deal To Transform Oil &amp; Gas Operations</a>
The Bears
&#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40995280/tesla-bull-dampens-enthusiasm-regarding-1010-robotaxi-event-but-heres-what-would-ta">Tesla Bull Dampens Enthusiasm Regarding 10/10 Robotaxi Event But Here&#8217;s What Would Take To Strengthen Fledgling Stock Recovery</a>,&#8221; by <a href="https://www.benzinga.com/author/shanthi-rexaline">Shanthi Rexaline</a>, covers Gary Black&#8216;s skepticism about Tesla Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) upcoming Robotaxi event as a stock catalyst, while highlighting optimism for a potential sub-$30K compact EV launch that could drive long-term growth for Tesla.
&#8220;<a href="https://www.benzinga.com/news/24/09/41016947/crowdstrike-executive-struck-by-regret-in-house-hearing-says-company-determined-to-prevent-instances">CrowdStrike Executive Struck By Regret In House Hearing, Says Company Determined To Prevent Instances Like Microsoft Outage From Repeating</a>,&#8221; by <a href="https://www.benzinga.com/author/ananya-gairola">Ananya Gairola</a>, reports Adam Meyers of CrowdStrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) apologized to lawmakers for the July global outage caused by a faulty update affecting systems running Microsoft software, promising to prevent future occurrences.
&#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41059769/peter-schiff-wants-to-know-if-bitcoin-fans-really-care-about-king-crypto-underperforming-g">Peter Schiff Wants To Know If Bitcoin Fans Really Care About King Crypto Underperforming Gold</a>,&#8221; by <a href="https://www.benzinga.com/author/aniket-verma">Aniket Verma</a>, highlights Peter Schiff&#8216;s critique of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investors for ignoring its 35% decline against gold since November 2021, despite significant media hype and interest in the cryptocurrency.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41000698/a-deflationary-nuclear-bomb-is-ticking-warns-economist-even-as-inflation-risks-wane">A &#8216;Deflationary Nuclear Bomb&#8217; Is Ticking, Warns Economist, Even As Inflation Risks Wane: &#8216;Cheaper It Gets, Cheaper Everything Gets&#8217;</a>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41049089/treasury-bond-etf-under-pressure-ahead-of-key-inflation-data-what-investors-should-know">Treasury Bond ETF Under Pressure Ahead Of Key Inflation Data: What Investors Should Know</a>
<a href="https://www.benzinga.com/markets/equities/24/09/41053761/american-eagle-sues-amazon-for-trademark-infringement-report">American Eagle Sues Amazon for Trademark Infringement: Report</a>
Keep up with all the latest breaking news and trading ideas by following<a href="https://twitter.com/Benzinga"> Benzinga</a><a href="http://twitter.com/Benzinga"> on Twitter</a>.
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Short Ideas

Tech

$BTC

$SHIB

AAPL

AMZN

CRWD

GOOG

GOOGL

MSFT

Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease

The Federal Reserve's preferred measure of inflation, the personal consumption expenditures index, grew less than economists expected in August at 2.2% <a href="https://www.benzinga.com/news/econ-s/24/09/41066122/feds-preferred-inflation-gauge-comes-in-below-expectations-for-august-easing-concerns-about-rising-p">year-over-year</a>. The data comes on the heels of the Federal Reserve's 0.5% interest rate cut issued Sept. 18, the first in <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">more than four years</a>.&nbsp;
The inflation data supports another 0.5% interest rate cut in November, RSM US LLP Chief Economist Joseph Brusuelas said in a Friday tweet. "This is what an economic expansion looks like at full employment," <a href="https://www.benzinga.com/news/24/09/41068393/inflation-decline-strengthens-confidence-in-feds-interest-rate-cut-if-you-were-second-guessing-the-f">he said</a>.&nbsp;
The S&amp;P 500 traded at all-time highs above the 5,700 level <a href="https://www.benzinga.com/markets/equities/24/09/41029448/s-p-500-hits-all-time-highs-nasdaq-100-tops-20k-ahead-of-key-economic-data-whats-driving-markets">this week</a>.
<h1 class="wp-block-heading">Brainard Touts China EV Ban In Detroit</h1>
Lael Brainard, the director of the National Economic Council and a former Federal Reserve board member, spoke in favor of the Biden administration's proposed ban on Chinese electric vehicles Monday at the Detroit Economic Club, the same day <a href="https://www.benzinga.com/markets/asia/24/09/40981254/chinese-vehicle-tech-faces-biden-administration-ban-over-national-security-concerns-china-ev-stocks">details of the proposal</a> were released. The U.S. Commerce Department aims to block the import and sale of Chinese-made vehicles with key communications and automated driving systems on the basis of national security concerns. Additionally, a 100% tariff on Chinese electric vehicles imposed by the Biden administration took effect Friday. 
"We will not allow cars driving on U.S. roads if they are using Chinese software and hardware systems," Brainard <a href="https://www.benzinga.com/markets/asia/24/09/40987608/biggest-risk-for-us-autos-biden-advisor-outlines-steps-to-counter-chinese-influence-on-the-industry">told the DEC</a>. "We think this is very important from a national security point of view."
<h1 class="wp-block-heading">Meta Platforms Dives Deeper Into AI, Virtual Reality</h1>
Facebook parent company Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) announced its latest Quest 3S virtual reality headset at the Meta Connect 2024 conference Wednesday along with updates to its Llama artificial intelligence platform and Ray-Ban smart glasses. CEO Mark Zuckerberg introduced a prototype for Orion, Meta's holographic <a href="https://www.benzinga.com/news/24/09/41032461/meta-unveils-new-ai-features-quest-3s-llama-3-2-holographic-orion-glasses-at-connect-2024-we-are-get">augmented reality glasses</a>. 
"This isn't passthrough. This is the physical world with holograms laid on it," Zuckerberg said.
<h1 class="wp-block-heading">China's Stimulus Triggers Stock Rally</h1>
The People's Bank of China announced <a href="https://www.benzinga.com/markets/asia/24/09/41003814/chinese-stocks-jump-as-central-bank-unveils-major-stimulus-to-spur-economy-a-step-in-the-right-direc">stimulus measures this week</a> that will inject approximately $140 billion (1 trillion yuan) in liquidity into the country's banking system as well as a reduction in the mortgage rate, sending U.S.-traded China stocks and ETFs such as e-commerce giant Alibaba Group Holding Ltd &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and electric vehicle manufacturer Nio Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) higher. 
Billionaire hedge fund manager David Tepper told CNBC's "Squawk Box" that he's building <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41050711/stocks-rise-as-china-signals-more-stimulus-billionaire-david-tepper-bets-big-on-everythi">positions in Chinese stocks</a>. "I didn't know that they were going to bring out the big guns," Tepper of the country's stimulus plans.&nbsp;
<h1 class="wp-block-heading">Bernie Sanders Blasts Ozempic Cost</h1>
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) CEO Lars Jorgensen faced questions from the Senate Health, Education, Labor and Pensions Committee Tuesday about the high prices of the drugs Ozempic and Wegovy. 
Wegovy, the weight loss version of diabetes drug Ozempic, costs $1,349 monthly in the U.S. versus $186 in Denmark, $140 in Germany and $92 in the U.K., according to the committee.
"You're making huge amounts of money in this country and you're charging us far more and you haven't given me an answer as to why," Sen. Bernie Sanders, the committee's chair, said to Jorgensen during the hearing.
The CEO said: "Anything that will help patients get access to affordable medicine, we'll be happy to look into."
Photo: Shutterstock.

Economics

BABA

Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 5 years by 22.36% on an annualized basis producing an average annual return of 36.66%. Currently, Novo Nordisk has a market capitalization of $536.41 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 5 years ago, it would be worth $4,660.74 today based on a price of $120.51 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727456441_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Shares of Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) fell sharply in today's pre-market trading after the SEC charged the company, two former executives for misleading claims about <a href="https://www.benzinga.com/quote/SAVA/news">Alzheimer&#8217;s clinical trial</a>.
Cassava Sciences shares dipped 10.8% to $28.40 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) shares tumbled 16.4% to $3.7600 in pre-market trading after the company announced a proposed public offering.</li>
<li>Uranium Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UEC#NYSE">UEC</a>) shares declined 5% to $6.05 in pre-market trading.</li>
<li>Udemy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) shares fell 4.6% to $7.76 in pre-market trading.</li>
<li>TORM plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) shares declined 4% to $33.96 in pre-market trading.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) shares declined 3.2% to $35.70 in pre-market trading after gaining over 2% on Thursday.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares fell 2.6% to $121.05 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41061540/s-p-hits-new-record-high-following-economic-reports-investor-optimism-improves-further-fear-index-r">S&amp;P Hits New Record High Following Economic Reports: Investor Optimism Improves Further, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

NVNO

SAVA

TRMD

UDMY

Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Consider Buying Potential Takeover Target Altimmune

UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The company's ...

UBS Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Eli Lilly's weight-loss drug no longer in shortage, FDA says

U.S. tweaks 2025 Medicare price negotiation process

Eli Lilly GLP-1 shortage officially ends, hurting Hims & Hers

BNY Mellon International Equity Fund Q2 2024 Commentary

BNY Mellon International Stock Fund Q2 2024 Commentary

Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH

Is Hims & Hers rally at risk as GLP-1 shortages ease?

Thermo Fisher plant making Astra/ Sanofi RSV drug reportedly breached FDA rules

ADDYY

AIQUF

AMGN

ANCTF

ASMIY

ASML

ATEYY

BKAG

BKCI

BKEM

BKGI

BKHY

BKIE

BKLC

BKMC

BKSE

BKUI

CNVVF

CTLT

DASTY

EXPGF

KYCCF

LVMHF

LZAGF

LZAGY

NONOF

NSRGY

RCRRF

SHECF

SIEGY

SNYNF

SZCRF

TCCPY

Screenshot 2024-09-10 at 4.29.40 PM

BRTX

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results

Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®

Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors

Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Management

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Comments

Novo Nordisk

ニュース

最新ニュース Novo Nordisk (NYSE:NVO) 株価情報

水曜日, 6 26, 2024

火曜日, 6 25, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル